L3VLUP
ProSign in

HALO · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

HALOAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • HALO
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterHALOAMGN
Q3 20208 holders, $540m16 holders, $16.3bn
Q4 20209 holders, $752m19 holders, $14.0bn
Q1 20217 holders, $712m16 holders, $14.5bn
Q2 20217 holders, $769m23 holders, $13.8bn
Q3 20217 holders, $648m24 holders, $11.6bn
Q4 20218 holders, $635m21 holders, $10.4bn
Q1 20227 holders, $611m23 holders, $9.9bn
Q2 202210 holders, $634m28 holders, $9.7bn
Q3 20228 holders, $537m21 holders, $7.9bn
Q4 20229 holders, $886m24 holders, $9.3bn
Q1 20236 holders, $339m22 holders, $8.4bn
Q2 20236 holders, $394m26 holders, $7.4bn
Q3 20233 holders, $527m26 holders, $8.7bn
Q4 20236 holders, $407m24 holders, $8.4bn
Q1 20245 holders, $326m25 holders, $6.7bn
Q2 20245 holders, $384m20 holders, $8.0bn
Q3 20245 holders, $409m21 holders, $8.8bn
Q4 20248 holders, $335m20 holders, $8.2bn
Q1 20259 holders, $539m25 holders, $12.0bn
Q2 202510 holders, $422m20 holders, $10.2bn
Q3 202514 holders, $1.1bn17 holders, $10.4bn
Q4 202513 holders, $885m19 holders, $18.0bn
Q1 202611 holders, $710m15 holders, $21.4bn
Q2 202611 holders, $732m23 holders, $24.9bn
HALO

Halozyme Therapeutics Inc

Holders
13
Reported value
$885m
Buyers
13
Sellers
23

Breadth -10 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
19
Reported value
$18.0bn
Buyers
13
Sellers
22

Breadth -9 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2025

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only HALO (8)

Arrowstreet Capital LP, Bridgewater Associates LP, D. E. Shaw & Co., Freestone Grove Partners LP, Hudson Bay Capital Management LP, Millennium Management LLC, Renaissance Technologies LLC, Voloridge Investment Management LLC

Only AMGN (14)

Acadian Asset Management LLC, ARK Investment Management LLC, Capital Research Global Investors, Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Man Group PLC, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Verition Fund Management LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →